Literature DB >> 16388516

Emodin inhibits vascular endothelial growth factor-A-induced angiogenesis by blocking receptor-2 (KDR/Flk-1) phosphorylation.

Hee-Jin Kwak1, Myung-Jin Park, Chang-Min Park, Sang-Ik Moon, Doo-Hyun Yoo, Hyung-Chahn Lee, Seung-Hoon Lee, Mi-Suk Kim, Hyean-Woo Lee, Woon-Seob Shin, In-Chul Park, Chang Hun Rhee, Seok-Il Hong.   

Abstract

Emodin (1,3,8-trihydroxy-6-methylanthraquinone), an active component in the root and rhizome of Rheum palmatum, is a tyrosine kinase inhibitor with a number of biological activities, including antitumor effects. Here, we examine the effects of emodin on vascular endothelial growth factor (VEGF)-A-induced angiogenesis, both in vitro and in vivo. In vitro, emodin dose-dependently inhibits proliferation, migration into the denuded area, invasion through a layer of Matrigel and tube formation of human umbilical vein endothelial cells (HUVECs) stimulated with VEGF-A. Emodin also inhibits basic fibroblast growth factor-induced proliferation and migration of HUVECs and VEGF-A-induced tube formation of human dermal microvascular endothelial cells. Specifically, emodin induces the cell cycle arrest of HUVECs in the G0/G1 phase by suppressing cyclin D1 and E expression and retinoblastoma protein phosphorylation, and suppresses Matrigel invasion by inhibiting the basal secretion of matrix metalloproteinase-2 and VEGF-A-stimulated urokinase plasminogen activator receptor expression. Additionally, emodin effectively inhibits phosphorylation of VEGF-A receptor-2 (KDR/Flk-1) and downstream effector molecules, including focal adhesion kinase, extracellular signal-regulated kinase 1/2, p38 mitogen-activated protein kinase, Akt and endothelial nitric oxide synthase. In vivo, emodin strongly suppresses neovessel formation in the chorioallantoic membrane of chick and VEGF-A-induced angiogenesis of the Matrigel plug in mice. Our data collectively demonstrate that emodin effectively inhibits VEGF-A-induced angiogenesis in vitro and in vivo. Moreover, inhibition of phosphorylation of KDR/Flk-1 and downstream effector molecules is a possible underlying mechanism of the anti-angiogenic activity of emodin. Based on these data, we propose that an interaction of emodin with KDR/Flk-1 may be involved in the inhibitory function of emodin toward VEGF-A-induced angiogenesis in vitro and responsible for its potent anti-angiogenic in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16388516     DOI: 10.1002/ijc.21641

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  22 in total

1.  Emodin, a natural anthraquinone, suppresses liver cancer in vitro and in vivo by regulating VEGFR2 and miR-34a.

Authors:  Jianguo Bai; Jianfei Wu; Ruifeng Tang; Chao Sun; Junwei Ji; Zhaolin Yin; Guangjun Ma; Wei Yang
Journal:  Invest New Drugs       Date:  2019-04-11       Impact factor: 3.850

Review 2.  Pleiotropic effects of herbs characterized with blood-activating and stasis-resolving functions on angiogenesis.

Authors:  Li Tao; Sheng Wang; Yang Zhao; Ai-Yun Wang; Lei Zhang; Jun-Shan Ruan; Fang-Tian Fan; Yu-Ping Liu; Yao Li; Zhi-Qiang Yue; Wen-Hui Qian; Wen-Xing Chen; Yin Lu
Journal:  Chin J Integr Med       Date:  2016-06-29       Impact factor: 1.978

3.  4-isothiocyanate-2, 2, 6, 6-tetramethyl piperidinooxyl inhibits angiogenesis by suppressing VEGFR2 and Tie2 phosphorylation.

Authors:  Yuanyuan Liu; Jing Gao; Shuangsheng Huang; Lamei Hu; Zhiqiang Wang; Zheyuan Wang; Xiao Chen; Xiaoyu Zhang; Wenguang Li
Journal:  Oncol Lett       Date:  2016-08-03       Impact factor: 2.967

4.  Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization.

Authors:  Young Sang Han; Ji Eun Lee; Ji Won Jung; Jong Soo Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-10-25       Impact factor: 3.117

5.  Involvement of matrix metalloproteinases on the inhibition of cells invasion and migration by emodin in human neuroblastoma SH-SY5Y cells.

Authors:  Hsu-Feng Lu; Kuang-Chi Lai; Shu-Chun Hsu; Hui-Ju Lin; Chao-Lin Kuo; Ching-Lung Liao; Jai-Sing Yang; Jing-Gung Chung
Journal:  Neurochem Res       Date:  2009-03-17       Impact factor: 3.996

6.  Emodin Inhibits Breast Cancer Growth by Blocking the Tumor-Promoting Feedforward Loop between Cancer Cells and Macrophages.

Authors:  Stephen Iwanowycz; Junfeng Wang; Johnie Hodge; Yuzhen Wang; Fang Yu; Daping Fan
Journal:  Mol Cancer Ther       Date:  2016-05-18       Impact factor: 6.261

7.  Emodin ameliorates high-glucose induced mesangial p38 over-activation and hypocontractility via activation of PPARgamma.

Authors:  Yi Liu; Lei Jia; Zun Chang Liu; Hong Zhang; Peng Ju Zhang; Qiang Wan; Rong Wang
Journal:  Exp Mol Med       Date:  2009-09-30       Impact factor: 8.718

Review 8.  Is Emodin with Anticancer Effects Completely Innocent? Two Sides of the Coin.

Authors:  Esra Küpeli Akkol; Iffet Irem Tatlı; Gökçe Şeker Karatoprak; Osman Tuncay Ağar; Çiğdem Yücel; Eduardo Sobarzo-Sánchez; Raffaele Capasso
Journal:  Cancers (Basel)       Date:  2021-05-31       Impact factor: 6.639

9.  Emodin suppresses maintenance of stemness by augmenting proteosomal degradation of epidermal growth factor receptor/epidermal growth factor receptor variant III in glioma stem cells.

Authors:  Jeongyub Kim; Jong-Seon Lee; Jieun Jung; Inhye Lim; Ji-Yun Lee; Myung-Jin Park
Journal:  Stem Cells Dev       Date:  2014-11-11       Impact factor: 3.272

10.  Antitumor activity of emodin against pancreatic cancer depends on its dual role: promotion of apoptosis and suppression of angiogenesis.

Authors:  Sheng-Zhang Lin; Wei-Tian Wei; Hui Chen; Kang-Jie Chen; Hong-Fei Tong; Zhao-Hong Wang; Zhong-Lin Ni; Hai-Bin Liu; Hong-Chun Guo; Dian-Lei Liu
Journal:  PLoS One       Date:  2012-08-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.